Health Care & Life Sciences » Biotechnology | Five Prime Therapeutics Inc.

Five Prime Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
13,791.00
19,231.00
379,801.00
30,691.00
39,508.00
49,868
SG&A Expense
41,518.00
55,253.00
91,150.00
128,161.00
188,397.00
191,003
EBIT
29,421.00
37,574.00
286,973.00
99,212.00
151,402.00
146,155
Unusual Expense
500.00
-
-
-
-
-
Non Operating Income/Expense
13.00
60.00
3.00
-
94.00
84
Pretax Income
28,872.00
37,424.00
287,457.00
96,745.00
148,518.00
140,447
Income Tax
-
-
37,810.00
31,048.00
1,704.00
-
Consolidated Net Income
28,872.00
37,424.00
249,647.00
65,697.00
150,222.00
140,447
Net Income
28,872.00
37,424.00
249,647.00
65,697.00
150,222.00
140,447
Net Income After Extraordinaries
28,872.00
37,424.00
249,647.00
65,697.00
150,222.00
140,447
Net Income Available to Common
28,872.00
37,424.00
249,647.00
65,697.00
150,222.00
140,447
EPS (Basic)
5.23
1.79
9.23
2.44
5.38
4.13
Basic Shares Outstanding
5,523.00
20,865.00
25,661.00
26,955.00
27,945.00
33,976
EPS (Diluted)
5.23
1.79
9.23
2.44
5.38
4.13
Diluted Shares Outstanding
5,523.00
20,865.00
27,035.00
26,955.00
27,945.00
33,976
EBITDA
27,727.00
36,022.00
288,651.00
97,470.00
148,889.00
141,135
Non-Operating Interest Income
62.00
210.00
487.00
2,467.00
2,978.00
5,792

About Five Prime Therapeutics

View Profile
Address
111 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.fiveprime.com
Updated 07/08/2019
Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on discovering and developing novel protein therapeutics. product candidates includes, Cabiralizumab(FPA008), Bemarituzumab(FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.